StageZero Life Sciences Ltd
14.3.2022 16:27:02 CET | ACCESS Newswire | Press release
This release replaces and corrects the release that was issued earlier this morning
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692951/CORRECTING-AND-REPLACING-StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Surmodics Opens Medical Device Coating Capabilities in Ireland10.9.2026 16:00:00 CEST | Press release
The Galway Facility Brings Nearly 50 Years of Coating Expertise, Cleanroom Coating Services and Analytical Testing Closer to Medical Device Manufacturers Across Ireland and Europe BALLINASLOE, COUNTY GALWAY, IRELAND / ACCESS Newswire / September 10, 2026 / Surmodics, Inc. today announced its expanded medical device coating capabilities in Galway, Ireland, expanding access to the company's Performance Coatings and coating services for medical device manufacturers throughout Ireland and Europe. The facility now includes dedicated cleanroom environments designed for medical device coating services and brings Surmodics' nearly 50 years of coating experience closer to one of the world's leading medical technology hubs. "Ireland is home to a significant concentration of medical device manufacturers and technology innovators, making it an important market for Surmodics and our customers," said Damien Kilcommons, Vice President of Site Operation at the Ireland facility. "By establishing dedica
MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 202610.9.2026 15:20:00 CEST | Press release
New modular approach will bring together MicroVision lidar hardware, perception software and open sensor integration to enable flexible perception solutions across applications REDMOND, WA AND HANOVER, GER / ACCESS Newswire / September 10, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception technologies, today announced plans to unveil its MicroVision Perception Platform™ at IAA Transportation 2026 in Hanover, Germany next week, marking the next evolution of the company's Lidar 2.0 strategy. The new modular platform is designed to bring together MicroVision's expanding portfolio of lidar hardware, perception software and open sensor integration into a flexible architecture that can be configured around the requirements of individual applications spanning automotive, commercial vehicles, industrial, security, defense and aerial use cases. Rather than relying on a fixed sensor configuration or closed "black box" solution, the MicroVision Perception Platform is being d
GA-ASI Unveils Wildfire UAS for Military, Civil and Commercial Roles10.9.2026 15:00:00 CEST | Press release
New Uncrewed Aircraft Combines Exceptional Endurance and Range with Unsurpassed Payload and Affordability at Scale SAN DIEGO, CA / ACCESS Newswire / September 10, 2026 / The world leader in Uncrewed Aircraft Systems, General Atomics Aeronautical Systems, Inc. (GA-ASI) is pleased to announce its groundbreaking Wildfire UAS, a clean-sheet aircraft designed to maximize future investments in large uncrewed aircraft that incorporates lessons learned over decades of large-scale global UAS operations. Wildfire draws upon more than 30 years of delivering more than 1,600 world-changing uncrewed aircraft, including the MQ-1B Predator®, MQ-9A Reaper®, MQ-9B SkyGuardian®, MQ-20 Avenger® and FQ-42A Collaborative Combat Aircraft. GA-ASI aircraft have amassed nearly 10 million total flight hours, mostly in combat, and introduced many of the technologies and concepts now emulated by others around the world. "This is exactly the right design for high-demand missions and cost-conscious customers," said
Steelcase Names Proven Growth Leader Irene Tasi as President9.9.2026 21:00:00 CEST | Press release
Experienced commercial and innovative leader will guide the Steelcase business as the company builds on its design leadership, dealer network and customer-focused strategy. GRAND RAPIDS, MI / ACCESS Newswire / September 9, 2026 / Steelcase today announced Irene Tasi has been named president of Steelcase and will lead the business effective September 14, 2026. Tasi brings more than 25 years of executive leadership experience with a track record leading complex businesses through growth, portfolio development, commercial execution, and organizational change. Her background includes full P&L responsibility, enterprise strategy, innovation, and sales and channel leadership. She will report to Jeff Lorenger, Chairman, President and Chief Executive Officer, HNI Corporation. "Irene brings a combination of commercial leadership, product innovation, operating discipline, and customer focus that makes her exceptionally well-suited to lead Steelcase," said Lorenger. "She has led businesses where
Global Study: Nursing Shortages Require Workforce Policy Solutions, Not Recruitment Campaigns Alone9.9.2026 15:01:00 CEST | Press release
Why people choose nursing, and why they leave, comes down to the same factors PHILADELPHIA, PA / ACCESS Newswire / September 9, 2026 / The global nursing shortage cannot be solved simply by encouraging more people to enter the profession, according to a new evidence brief from the Global Nursing Workforce Centre (GNWC), a joint initiative of the International Council of Nurses (ICN) and TruMerit®. Drawing on research from 42 countries, the brief, The Attractiveness of Nursing for Prospective and Current Nursing Students, finds that the factors influencing people to choose nursing are often the same ones that determine whether they stay. Working conditions, compensation, professional respect, career development opportunities, workplace experiences, and the ability to provide quality care all shape nursing attractiveness to current nurses as well as potential recruits. The findings suggest that countries seeking to strengthen their nursing workforce must focus not only on recruitment, bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom